STOCK TITAN

INVO Fertility Q3 2026 loss narrows to $2.15M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

INVO Fertility, Inc. reported third-quarter 2026 revenue of $2,222,656, up 26% from $1,757,094 a year earlier; consolidated clinic revenue rose 28% to $2,207,587 from $1,722,223. The company attributed clinic growth to higher revenue in Wisconsin and Atlanta and contributions from its Indiana and Birmingham clinics.

Net loss narrowed to $2,149,920 from $3,395,598, and loss from operations narrowed to $1,477,360 from $1,635,484. Clinic-Level Adjusted EBITDA, a non-GAAP measure before corporate operating and public-company expenses, was $292,114 versus $243,120, the seventh consecutive positive quarter. The planned Birmingham acquisition transition reduced the quarter’s clinic-level contribution by approximately $193,000. Consolidated Adjusted EBITDA was ($961,704) versus ($947,568).

At September 30, 2026, cash was $3,695,770 and current liabilities were $4,457,529, compared with $2,077,842 and $10,331,629, respectively, at December 31, 2025. INVO acquired the remaining 50% interest in its Birmingham clinic in June for an agreed purchase price of $175,001, payable to the sellers.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointQ3 revenue rose 26%; consolidated clinic revenue rose 28%.
  • Moderate pointQuarterly net loss narrowed to $2,149,920 from $3,395,598.
  • Moderate pointClinic-Level Adjusted EBITDA reached $292,114, its seventh consecutive positive quarter.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Total revenue $2,222,656 Three months ended September 30, 2026; up 26% from $1,757,094 in Q3 2025.
Consolidated clinic revenue $2,207,587 Three months ended September 30, 2026; up 28% from $1,722,223 in Q3 2025.
Net loss ($2,149,920) Three months ended September 30, 2026; compared with ($3,395,598) in Q3 2025.
Loss from operations ($1,477,360) Three months ended September 30, 2026; compared with ($1,635,484) in Q3 2025.
Clinic-Level Adjusted EBITDA $292,114 Three months ended September 30, 2026; compared with $243,120 in Q3 2025.
Consolidated Adjusted EBITDA ($961,704) Three months ended September 30, 2026; compared with ($947,568) in Q3 2025.
Cash $3,695,770 At September 30, 2026; $2,077,842 at December 31, 2025.
Current liabilities $4,457,529 At September 30, 2026; $10,331,629 at December 31, 2025.
Adjusted EBITDA financial
"Consolidated Adjusted EBITDA was $(1.0) million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Clinic-Level Adjusted EBITDA financial
"Clinic-Level Adjusted EBITDA was $292,114"
Clinic-level adjusted EBITDA measures a single clinic’s core operating profit before interest, taxes, depreciation and amortization, with additional one-off, non-cash or non-operational items removed so the number reflects recurring cash earnings from running that clinic. Think of it as the clinic’s day-to-day cash profit after stripping out accounting entries and unusual events; investors use it to compare profitability across clinics and assess underlying business performance independent of financing or tax differences.
non-GAAP financial measures financial
"which are non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
assisted reproductive technology medical
"expanding access to assisted reproductive technology care"
Assisted reproductive technology (ART) is a set of medical procedures used to help people conceive when natural conception is difficult or impossible, including techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection, egg or sperm donation, embryo transfer and related laboratory and drug treatments. Think of it as a high-tech toolkit that replaces or assists parts of the natural fertilization process; it matters to investors because ART services and products are driven by patient demand, regulatory rules, reimbursement policies and technological advances, all of which affect clinic volumes, device and drug sales, and long-term revenue potential.
in vitro fertilization medical
"including in vitro fertilization (IVF)"
In vitro fertilization (IVF) is a medical procedure that fertilizes an egg with sperm outside the body in a laboratory dish, then transfers the resulting embryo to a uterus to achieve pregnancy. Investors care because IVF drives demand for specialized clinics, medical devices, drugs, and insurance coverage—similar to how a new product line creates sales and service needs—so changes in treatment success rates, regulation, or patient demand can affect revenues and costs across healthcare and biotech companies.
intravaginal culture medical
"the intravaginal culture (IVC) procedure"
A fertility technique in which eggs and sperm are placed together inside a small, sealed device that is inserted into the woman’s vagina so fertilization and initial embryo development occur using body heat instead of a full laboratory incubator. For investors, it matters because it can lower clinic costs, broaden access to assisted reproduction, and shift demand toward smaller medical devices and different regulatory and reimbursement pathways—similar to moving part of a factory process back into the customer's hands.
Total revenue $2,222,656 Up 26% from $1,757,094 in Q3 2025
Consolidated clinic revenue $2,207,587 Up 28% from $1,722,223 in Q3 2025
Net loss ($2,149,920) Narrowed from ($3,395,598) in Q3 2025
Clinic-Level Adjusted EBITDA $292,114 Compared with $243,120 in Q3 2025; seventh consecutive positive quarter
Consolidated Adjusted EBITDA ($961,704) Compared with ($947,568) in Q3 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did INVO Fertility (IVF) report for Q3 2026?

INVO Fertility reported third-quarter 2026 revenue of $2,222,656, compared with $1,757,094 in Q3 2025. Consolidated clinic revenue was $2,207,587, compared with $1,722,223.

How much cash and current liabilities did INVO (IVF) report at September 30, 2026?

At September 30, 2026, INVO had cash of $3,695,770 and current liabilities of $4,457,529. At December 31, 2025, those amounts were $2,077,842 and $10,331,629, respectively.

What did INVO (IVF) pay for the remaining Birmingham clinic interest?

INVO acquired the remaining 50% interest in its Birmingham clinic in June 2026 for an agreed purchase price of $175,001, payable to the sellers. The price reflected expected investments under full ownership, including recruiting a new physician and adding services, as well as temporary revenue disruption while the physician ramps up.

How many INVO (IVF) shares were outstanding in November 2026?

INVO reported 1,192,860 common shares outstanding as of November 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001417926 0001417926 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 16, 2026

 

INVO FERTILITY, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39701   20-4036208

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

5582 Broadcast Court

Sarasota, FL 34240

(Address of principal executive offices, including zip code)

 

(978) 878-9505

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   IVF   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 16, 2026, INVO Fertility, Inc. (the “Company”), issued a press release announcing financial results for the quarter ended September 30, 2026. The text of the press release is furnished as Exhibit 99.1 to this current report.

 

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated November 16, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document.)

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 INVO FERTILITY, INC.
   
  /s/ Steven Shum
  Steven Shum
  Chief Executive Officer

 

-3-

 

 

Exhibit 99.1

 

INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA

 

Record quarterly clinic revenues supported by both organic growth and acquisitions

 

Seventh consecutive quarter of positive Clinic-Level Adjusted EBITDA

 

Balance sheet continues to improve following debt repayments

 

SARASOTA, Fla., November 16, 2026 — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility”, “INVO”, or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the third quarter ended September 30, 2026.

 

Q3 2026 Financial Highlights (all metrics compared to Q3 2025 unless otherwise noted)

 

●Revenue increased 26% to $2,222,656 from $1,757,094.
●Consolidated clinic revenue increased 28% to $2,207,587 from $1,722,223.
●Net loss narrowed to $2.1 million from $3.4 million. Loss from operations improved to $1.5 million from $1.6 million.
●Clinic-Level Adjusted EBITDA before corporate operating and public company expenses remained positive for the seventh consecutive quarter.
●Consolidated Adjusted EBITDA was $(1.0) million, compared to $(0.9) million in Q3 2025.
●Cash was $3.7 million at September 30, 2026, or approximately $3.10 per share.
●As of November 13, 2026, the Company had 1,192,860 shares of common stock outstanding.
●Further strengthening of the balance sheet compared to December 31, 2025 with assets increasing by $5.3 million, liabilities reduced by $5.5 million, and net equity of $18.0 million, or $15.09 per share.

 

Recent Highlights

 

●Organic and acquired growth. Revenue grew at both the Wisconsin and Atlanta clinics as the practices continued their efforts to reach more patients. Management believes that Wisconsin’s entry into the Progyny network in the first quarter contributed to growth by expanding access for patients with Progyny coverage. The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each contributed a full quarter of revenue.
●Clinic efficiency. INVO has implemented, and continues to evaluate, new tools to reduce time spent on documentation and administrative work across its practices, drawing on industry best practice. These initiatives are expected to continue driving improved patient experience and clinic-level efficiencies.
●Positive industry feedback at ASRM. In October 2026, INVO attended the American Society for Reproductive Medicine Scientific Congress & Expo in Baltimore, resulting in further expansion of potential acquisition opportunities.
●Improved balance sheet. INVO ended September with $3.7 million in cash and $4.5 million in current liabilities, down from $10.3 million in current liabilities at year-end 2025.

 

 

 

 

●Planned investment in Birmingham. In June 2026, INVO acquired the remaining 50% interest in its Birmingham clinic for an agreed purchase price of $175,001 payable to the sellers. The purchase price reflected the investments INVO expected to make under full ownership, including recruiting a new physician and adding key services, and the temporary revenue disruption as the new physician ramps up.
●Continued clinic-level profitability. The clinic network generated approximately $292,000 in Clinic-Level Adjusted EBITDA, its seventh consecutive positive quarter, after accounting for the approximate $193,000 impact in Q3 of the planned Birmingham acquisition transitioning.

 

Management Commentary

 

“Revenue grew again this quarter, and our clinics continued to generate positive Adjusted EBITDA before corporate expenses,” said Steve Shum, Chief Executive Officer of INVO Fertility. “We saw growth at our Wisconsin and Atlanta practices alongside the contribution from our acquisitions of the Indiana clinic and Birmingham clinic. That combination is what we set out to achieve by investing in our existing clinics and acquiring established practices.”

 

“We continue to see increased opportunities for acquisitions, which remain a key component to our growth objectives, as independent fertility practices look for ways to serve more patients while preserving the local relationships that patients and physicians value. As a publicly traded fertility clinic operator, INVO provides public market investors an alternative way to participate directly in that evolution and share in the potential growth of our clinic network. Equally important, we have purposely made key investments in people and additional infrastructure, in advance, in preparation to expand our network. We believe we have assembled an excellent team capable of executing on our growth plans and we look forward to leveraging our infrastructure as we expand and driving further operating performance.”

 

“Our balance sheet has also further strengthened in the period following the Wisconsin acquisition payment and the reduction in our current liabilities. We’re also focused on helping our clinics reach more patients and giving our clinical teams better tools and resources. Overall, the progress we’ve made and the opportunities we see on both sides of our growth strategy give us good reason to be excited about what comes next,” Shum concluded.

 

Third Quarter Financial Discussion

 

Revenue increased to approximately $2.2 million in the third quarter of 2026 from approximately $1.8 million in the prior-year quarter. Clinic revenue accounted for approximately $485,000 of year-over-year growth, reflecting higher revenue in Wisconsin and Atlanta and the addition of the Indiana and Birmingham clinics. Product revenue was approximately $15,000, compared to approximately $35,000 a year earlier. The decrease in product revenue partially reflects the elimination of sales to the Indiana and Birmingham clinics, which are now consolidated subsidiaries and treated as intercompany transactions.

 

 

 

 

Cost of services was approximately $1.4 million in the third quarter of 2026, primarily reflecting the cost of providing care across the expanded clinic network. Selling, general, and administrative expenses were approximately $2.1 million, compared to approximately $2.1 million a year earlier.

 

Loss from operations improved to approximately $1.5 million in the third quarter of 2026 from $1.6 million in the prior year. Net loss narrowed to approximately $2.1 million from approximately $3.4 million in the year-ago quarter.

 

Consolidated Adjusted EBITDA was $(1.0) million in the third quarter of 2026, compared with $(0.9) million in the prior-year quarter. This measure includes the cost of operating the public company and supporting the clinic network, including personnel in operations, human resources, and finance.

 

Clinic-Level Adjusted EBITDA was $292,114, compared with $243,120 in the prior-year quarter. The clinics generated positive Adjusted EBITDA before corporate expenses for the seventh consecutive quarter. The planned transition in Birmingham reduced the quarter’s clinic-level contribution by approximately $193,000 due to the anticipated revenue disruption and increased costs associated with bringing in a new physician.

 

At September 30, 2026, cash totaled approximately $3.7 million and current liabilities were approximately $4.5 million, compared to $2.1 million and $10.3 million, respectively, at December 31, 2025.

 

Clinic-Level Adjusted EBITDA

 

Clinic-Level Adjusted EBITDA was $292,114 in the third quarter of 2026, compared with $243,120 in the third quarter of 2025. The clinic network generated positive Adjusted EBITDA for the seventh consecutive quarter.

 

Management is focused on growing this contribution through higher patient volumes, expanded services, and improved operating execution, while also adding (via its acquisition efforts) established, profitable clinics that can increase scale and allow corporate operating expenses to be supported across a larger revenue and earnings base.

 

(Unaudited, in dollars, before corporate operating and public company expenses)

 

 

Fertility Clinic Services Segment  Q3 2026   Q3 2025 
Clinic revenue  $2,207,587   $1,722,223 
Operating expenses   2,144,678    1,592,534 
Segment profit   62,909    129,689 
Depreciation and amortization   36,273    113,431 
Birmingham clinic – acquisition transition   192,932    - 
Clinic-Level Adjusted EBITDA  $292,114   $243,120 

 

Clinic-Level Adjusted EBITDA is a non-GAAP measure. See Use of Non-GAAP Measures and the reconciliation below. Fertility Clinic Services Segment data derived from Note 15 – Segment Reporting in the Company’s third quarter 10-Q

 

 

 

 

Webcast

 

INVO Fertility will host a webcast to discuss its third quarter 2026 financial results and provide a business update.

 

Date and time: Monday, November 16, 2026, at 11:00 a.m. Eastern Time

 

Webcast registration: https://app.webinar.net/2WBLVyGJEq9

 

Replay: https://app.webinar.net/2WBLVyGJEq9

 

Use of Non-GAAP Measure

 

Included in this press release are references to Adjusted EBITDA and Clinic-Level Adjusted EBITDA, which are non-GAAP financial measures. These measures are not intended to be substitutes for financial measures reported in accordance with U.S. generally accepted accounting principles. Management believes that, when considered together with the GAAP figures, these measures provide meaningful information regarding operating performance, the earnings contribution of the Company’s clinic platform and trends in the business.

 

Clinic-Level Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations before corporate operating expenses, as calculated by management. This measure is intended to provide visibility into the performance and earnings capacity of the operating clinic platform separately from the costs associated with managing a public company and building a larger acquisition platform. Adjusted EBITDA and Clinic-Level Adjusted EBITDA may be calculated differently by INVO Fertility than by other companies that disclose measures with the same or similar terms.

 

About INVO Fertility

 

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.

 

Safe Harbor Statement

 

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements regarding organic growth initiatives, acquisition opportunities, integration of acquired clinics, balance sheet improvements, liquidity, the growth of our clinic platform and our ability to achieve cash flow break even or profitability, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

 

For more information, please contact:

 

INVO Fertility, Inc.

Steve Shum, CEO

978-878-9505

sshum@invofertility.com

 

Investor Contact

 

Lytham Partners, LLC

Robert Blum

602-889-9700

INVO@lythampartners.com

 

 

 

 

INVO FERTILITY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

  

For the Three Months Ended

September 30,

  

For the Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
                 
Revenue:                    
Clinic revenue  $2,207,587   $1,722,223   $6,357,605   $5,175,870 
Product revenue   15,069    34,871    55,761    82,063 
Total revenue   2,222,656    1,757,094    6,413,366    5,257,933 
Operating expenses:                    
Cost of services   1,436,870    1,121,174    4,071,782    3,252,659 
Cost of goods sold   14,144    6,575    79,443    13,622 
Selling, general, and administrative expenses   2,071,438    2,128,088    6,154,287    5,878,459 
Impairment loss   -    -    -    1,397,353 
Depreciation and amortization   177,564    136,741    465,835    540,940 
Total operating expenses   3,700,016    3,392,578    10,771,347    11,083,033 
Loss from operations   (1,477,360)   (1,635,484)   (4,357,981)   (5,825,100)
Other income (expense):                    
Gain from equity method joint ventures   -    12,827    15,014    8,012 
Gain on remeasurement   -    -    2,452,032    - 
Gain (loss) on change in fair value of derivatives   (562,997)   (33,566)   (4,353,222)   1,626,594 
Loss on debt extinguishment   -    (1,416,610)   (172,621)   (2,108,880)
Gain on settlement   -    -    -    939,500 
Interest income   74,735    -    214,249    - 
Interest expense   (154,768)   (322,765)   (512,318)   (1,071,200)
Total other income (expense)   (643,030)   (1,760,114)   (2,356,866)   (605,974)
Net loss from continuing operations before income taxes   (2,120,390)   (3,395,598)   (6,714,847)   (6,431,074)
Provision for income taxes   29,530    -    85,684    - 
Net loss from continuing operations   (2,149,920)   (3,395,598)   (6,800,531)   (6,431,074)
Discontinued operations (Note 5)                    
Loss on disposal of NTI   -    -    -    (1,534,517)
Loss on discontinued operations of NTI   -    -    -    (16,452,562)
Net loss  $(2,149,920)  $(3,395,598)  $(6,800,531)  $(24,418,153)
                     
Net Loss from continuing operations per share                    
Basic  $(2.44)  $(157.43)  $(11.20)  $(722.84)
Diluted  $(2.44)  $(157.43)  $(11.20)  $(722.84)
Loss from discontinued operations per common share                    
Basic  $-   $-   $-   $(2,021.70)
Diluted  $-   $-   $-   $(2,021.70)
Net Loss per common share:                    
Basic  $(2.44)  $(157.43)  $(11.20)  $(2,744.54)
Diluted  $(2.44)  $(157.43)  $(11.20)  $(2,744.54)
Weighted average number of common shares outstanding:                    
Basic   880,233    21,569    607,101    8,897 
Diluted   880,233    21,569    607,101    8,897 

 

 

 

 

INVO FERTILITY, INC.

CONSOLIDATED BALANCE SHEETS

 

  

September 30,

2026

  

December 31,

2025

 
   (Unaudited)     
ASSETS          
Current assets          
Cash  $3,695,770   $2,077,842 
Accounts receivable, net of allowances of $140,089 and $69,641 as of September 30, 2026 and December 31, 2025, respectively   170,423    217,263 
Inventory, net of allowances of $0 as of September 30, 2026 and December 31, 2025   230,806    225,253 
Prepaid expenses and other current assets   347,840    241,145 
Total current assets   4,444,839    2,761,503 
Property and equipment, net   814,175    386,165 
Lease right of use   2,052,056    1,286,217 
Intangible assets, net   1,245,345    1,325,145 
Goodwill   9,236,642    5,878,986 
Investment in NAYA Therapeutics   2,466,810    2,466,810 
Note receivable – NAYA Therapeutics   5,240,333    5,029,770 
Note receivable – HRCFG   -    1,085,528 
           
Total assets  $25,500,200   $20,220,124 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued liabilities  $1,297,870   $2,034,057 
Accrued compensation   377,110    285,946 
Notes payable - current portion, net   577,108    394,664 
Convertible note payable - related party, net   17,882    880,000 
Deferred revenue   728,630    721,897 
Lease liability, current portion   413,117    208,987 
Additional payments for acquisitions, current portion   998,000    3,925,000 
Warrant liability   -    1,881,078 
Other current liabilities   47,812    - 
Total current liabilities   4,457,529    10,331,629 
Lease liability, net of current portion   1,769,838    1,171,075 
Liability for excess losses of equity method investee   -    448,474 
Notes payable – net of current portion   362,445    744,725 
Derivative liability   745,288    - 
Deferred tax liability   80,159    - 
Other liabilities, net of current portion   79,688    - 
Additional payments for acquisition, net of current portion   -    300,000 
Total liabilities  $7,494,947   $12,995,903 
           
Stockholders’ equity          
Series C-2 Preferred Stock, $1,000.00 par value; 20,000 shares authorized; 0 and 3,004 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  $-   $2,406,359 
Series D Preferred Stock, $1,000.00 par value, 400 shares authorized; 400 and 0 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   400,000    - 
           
Common Stock, $.0001 par value; 62,500,000 shares authorized; 1,192,860 and 119,358 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   119    11 
Additional paid-in capital   115,790,672    96,187,254 
Accumulated deficit   (98,185,538)   (91,369,403)
Total stockholders’ equity   18,005,253    7,224,221 
Total liabilities and stockholders’ equity  $25,500,200   $20,220,124 

 

 

 

 

Adjusted EBITDA

 

   For the Three Months Ended 
   September 30, 
   2026   2025 
Net loss from continuing operations  $(2,149,920)  $(3,395,598)
Interest expense   154,768    322,765 
Interest income   74,735    - 
Tax expense   29,530    - 
Depreciation and amortization   177,564    136,741 
Stock-based compensation   188,622    493,348 
Non cash compensation for services   -    45,000 
Gain on remeasurement   -    - 
Gain on change in fair value of warrant liability   562,997    33,566 
Loss from debt extinguishment   -    1,416,610 
Adjusted EBITDA  $(961,704)  $(947,568)

 

 

 

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading